Detection of mixed populations of wild-type and YMDD hepatitis B variants by pyrosequencing in acutely and chronically infected patients
<p><b>Abstract</b></p> <p><b>Background</b></p> <p>Lamivudine (LAM) is associated with the highest known rate of resistance mutations among nucleotide analogs used to treat chronic hepatitis B virus (HBV) infection. Despite this, LAM continues in...
Main Authors: | Mello Francisco C A, Lago Bárbara V, Lewis-Ximenez Lia L, Fernandes Carlos A, Gomes Selma A |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2012-07-01
|
Series: | BMC Microbiology |
Online Access: | http://www.biomedcentral.com/1471-2180/12/96 |
Similar Items
-
YMDD and FLLAQ Mutations in Chronic Hepatitis B Patients
by: Rezanezhadi, M, et al.
Published: (2015-01-01) -
Detection of the YMDD Motif Mutations Rate in Chronic Hepatitis B Patients Treated with Lamivudine
by: Soudbakhsh A, et al.
Published: (2011-06-01) -
Detection of the YMDD Motif Mutations Rate in Chronic Hepatitis B Patients Treated with Lamivudine
by: R Rafiei Tabatabaei, et al.
Published: (2011-06-01) -
Frequency of YMDD Mutations in Patients with Chronic Hepatitis B Untreated with Antiviral Medicines
by: Hossein Keyvani, et al.
Published: (2011-12-01) -
Detection of the YMDD Motif Mutations Rate in Chronic Hepatitis B Patients Treated with Lamivudine
by: R Ehsani
Published: (2012-05-01)